High affinity HERG K+ channel blockade by the antiarrhythmic agent dronedarone:: resistance to mutations of the S6 residues Y652 and F656

被引:72
作者
Ridley, JM
Milnes, JT
Witchel, HJ
Hancox, JC
机构
[1] Sch Med Sci Bristol, Dept Physiol, Bristol BS8 1TD, Avon, England
[2] Sch Med Sci Bristol, Cardiovasc Res Labs, Bristol BS8 1TD, Avon, England
关键词
acquired long QT syndrome; amiodarone; antiarrhythmic; delayed rectifier; dronedarone; F656; F656A; Hun an-ether-a-go-go-related gene; I-K; long QT syndrome; potassium channel; QT prolongation; Y652; Y652A;
D O I
10.1016/j.bbrc.2004.10.127
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pharmacological inhibition of human-ether-a-go-go-related gene (HERG) K+ channels by structurally and therapeutically diverse drugs is associated with the 'acquired' form of long QT syndrome and with potentially lethal cardiac arrhythmias. Two aromatic amino-acid residues (Y652 and F656) on the inner (S6) helices are considered to be key constituents of a high affinity drug binding site within the HERG channel pore cavity. Using wild-type (WT) and mutant HERG channels expressed in mammalian cell lines, we have investigated HERG channel current (I-HERG) blockade at 37 +/- 1 degreesC by dronedarone (DRONED), a non-iodinated analogue of the Class III antiarrhythmic agent amiodarone (AMIOD). Under our conditions WT I-HERG tails, measured at -40 mV following activating pulses to +30 mV, were blocked with IC50 values of similar to59 and 70 nM for DRONED and AMIOD, respectively. IHERG inhibition by DRONED was contingent upon channel gating, with block developing rapidly on membrane depolarization, but with no preference for activated over inactivated channels. High external [K+] (94 mM) reduced the potency of I-HERG inhibition by both DRONED and AMIOD. Strikingly, mutagenesis to alanine of the S6 residue F656 (F656A) failed to eliminate blockade by both DRONED and AMIOD, whilst Y652A had comparatively little effect on DRONED but some effect on AMIOD. These findings demonstrate that high affinity drug blockade of IHERG can occur without a strong dependence on the Y652 and F656 aromatic amino-acid residues. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:883 / 891
页数:9
相关论文
共 29 条
[1]   Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels [J].
Chen, J ;
Seebohm, G ;
Sanguinetti, MC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) :12461-12466
[2]   Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels [J].
Chiu, PJS ;
Marcoe, KF ;
Bounds, SE ;
Lin, CH ;
Feng, JJ ;
Lin, A ;
Cheng, FC ;
Crumb, WJ ;
Mitchell, R .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 95 (03) :311-319
[3]  
Doggrell S A, 2001, Expert Opin Pharmacother, V2, P1877, DOI 10.1517/14656566.2.11.1877
[4]   Dronedarone: an arniodarone analogue [J].
Doggrell, SA ;
Hancox, JC .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (04) :415-426
[5]   In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C - Electrophysiological, anti-adrenergic, and anti-angiotensin II effects [J].
Gautier, P ;
Guillemare, E ;
Djandjighian, L ;
Marion, A ;
Planchenault, J ;
Bernhart, C ;
Herbert, JM ;
Nisato, D .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2004, 44 (02) :244-257
[6]   Electrophysiologic characterization of dronedarone in guinea pig ventricular cells [J].
Gautier, P ;
Guillemare, E ;
Marion, A ;
Bertrand, JP ;
Tourneur, Y ;
Nisato, D .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 41 (02) :191-202
[7]   Open channel block of HERG K+ channels by vesnarinone [J].
Kamiya, K ;
Mitcheson, JS ;
Yasui, K ;
Kodama, I ;
Sanguinetti, MC .
MOLECULAR PHARMACOLOGY, 2001, 60 (02) :244-253
[8]   Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels [J].
Kiehn, J ;
Thomas, D ;
Karle, CA ;
Schöls, W ;
Kübler, W .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (03) :212-219
[9]   Cellular electropharmacology of amiodarone [J].
Kodama, I ;
Kamiya, K ;
Toyama, J .
CARDIOVASCULAR RESEARCH, 1997, 35 (01) :13-29
[10]  
Lees-Miller JP, 2000, MOL PHARMACOL, V57, P367